The CE/IVD marked suPARnostic® ELISA assay is a full quantifiable method.

The suPARnostic® ELISA assay is based on a simplified double monoclonal antibody sandwich ELISA* assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells.

The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples.
suPAR concentrations are determined as ng/mL plasma.

*For further information on the sandwich ELISA technology please visit Wikipedia



Clinical Benefits of ELISA suPARnostic®:

  • Triaging – Adds to clinical decision making, when selecting patients for admission.
  • Predicting Patient Survival – suPARnostic® beats other biomarkers as well as most used clinical scores.